Artificial intelligence promises to speed the development of new medicines, but it also introduces a troubling dynamic for biopharmaceutical innovators. According to an IPWatchdog analysis, the same technology that helps researchers identify promising compounds can be turned against them by "super-fast followers"—competitors who mine newly published patent applications and scientific literature to generate related variants and file their own patent claims in days, before doing the work needed to establish a genuine invention.
The concern is not that these competitors will immediately bring a drug to market, but that they may secure early filing positions around future development opportunities without committing comparable resources. The article notes that some AI-generated hypotheticals may be hallucinations or lack human conception, yet the speed of filing can become a business weapon against the pioneer whose research made the opportunity visible. This shifts the competitive landscape in ways the patent framework, designed before such industrial-scale automation, may not handle well.
At the heart of the issue is the patent bargain: society grants limited exclusivity in exchange for a useful disclosure. If AI allows competitors to extract that disclosure and rapidly file blocking claims, the pioneer may lose the ability to justify the billions of dollars needed for original research, development, and regulatory approval. The article cites a Wall Street Journal report on Chinese companies studying Western patents, including a microblog that analyzed a Novartis paper and related filings within four days, as evidence of the accelerating trend.
The author argues that the patent incentive structure should be reexamined in light of these competitive dynamics. While the system can tolerate a few questionable filings, systematic AI-gaming of patent acquisition could ultimately reduce the number of new medicines if investors lose confidence in the economic rewards of pioneering research.